GNOME

Gnome Sciences is a molecular pathology and translational research company that provides advanced biomarker analysis and diagnostic support to the pharmaceutical and biotechnology industries. Operating from a CLIA-certified and GLP-compliant laboratory, the company specializes in high-resolution tissue analysis, immunohistochemistry (IHC), and custom assay design. Beyond its role as a Contract Research Organization (CRO), Gnome Sciences conducts internal research, recently gaining significant attention for discovering that the BCL2 inhibitor Venclexta (venetoclax) can potentially halt the progression of Amyotrophic Lateral Sclerosis (ALS). The company is currently advancing clinical evaluations of BCL2-targeting therapies for neurodegenerative conditions.